See more : Internet Infinity, Inc. (ITNF) Income Statement Analysis – Financial Results
Complete financial analysis of Eupraxia Pharmaceuticals Inc. (EPRX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Eupraxia Pharmaceuticals Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Moody’s Corporation (MCO) Income Statement Analysis – Financial Results
- NextStage SCA (NEXTS.PA) Income Statement Analysis – Financial Results
- Source Rock Royalties Ltd. (SRR.V) Income Statement Analysis – Financial Results
- Moody Technology Holdings Limited (1400.HK) Income Statement Analysis – Financial Results
- Sunniva Inc. (SNNVF) Income Statement Analysis – Financial Results
Eupraxia Pharmaceuticals Inc. (EPRX)
Industry: Biotechnology
Sector: Healthcare
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 209.91K | 193.27K | 111.53K | 116.81K | 201.94K | 125.83K | 85.38K |
| Gross Profit | -209.91K | -193.27K | -111.53K | -116.81K | -201.94K | -125.83K | -85.38K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 27.54M | 17.20M | 9.68M | 859.78K | 2.94M | 6.64M | 3.19M |
| General & Administrative | 9.65M | 5.81M | 8.89M | 1.27M | 3.01M | 7.54M | 1.70M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 9.65M | 5.81M | 8.89M | 1.27M | 3.01M | 7.54M | 1.70M |
| Other Expenses | 0.00 | 0.00 | -2.26M | 0.00 | 1.74K | 0.00 | 0.00 |
| Operating Expenses | 37.92M | 23.20M | 18.68M | 2.25M | 6.16M | 14.31M | 4.97M |
| Cost & Expenses | 37.92M | 23.20M | 18.68M | 2.25M | 6.16M | 14.31M | 4.97M |
| Interest Income | 407.04K | 569.32K | 65.73K | 427.00 | 12.04K | 1.11K | 330.00 |
| Interest Expense | 1.58M | 1.59M | 1.30M | 1.88M | 1.46M | 142.17K | 52.81K |
| Depreciation & Amortization | 209.91K | 193.27K | 111.53K | 116.81K | 201.94K | 125.83K | 85.38K |
| EBITDA | -36.75M | -22.14M | -21.96M | -2.01M | -5.94M | -14.57M | -4.89M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -36.90M | -22.63M | -20.87M | -2.25M | -6.15M | -14.31M | -4.97M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -2.29M | -64.07K | -5.46M | -1.76M | -1.08M | -2.95M | -143.13K |
| Income Before Tax | -39.18M | -23.92M | -23.37M | -4.01M | -7.24M | -14.83M | -5.00M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -89.67K | 930.52K | -1.34M | 1.87M | 1.40M | -1.46M | -627.56K |
| Net Income | -37.39M | -23.26M | -22.99M | -4.00M | -7.18M | -13.23M | -4.32M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.58 | -1.21 | -1.61 | -0.31 | -0.56 | -1.03 | -0.34 |
| EPS Diluted | -1.58 | -1.21 | -1.61 | -0.31 | -0.56 | -1.03 | -0.34 |
| Weighted Avg Shares Out | 24.15M | 19.29M | 14.24M | 12.87M | 12.87M | 12.87M | 12.87M |
| Weighted Avg Shares Out (Dil) | 24.15M | 19.29M | 14.24M | 12.87M | 12.87M | 12.87M | 12.87M |
Eupraxia Pharmaceuticals to Host Virtual KOL Event on EP-104GI Clinical Development Program for Eosinophilic Esophagitis ("EoE") on May 29, 2024
VICTORIA, BC , May 22, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology to optimize drug delivery for applications with significant unmet need, today announced that...
Eupraxia Pharmaceuticals Announces New Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis
Trial's first and second cohorts maintaining signs of potential efficacy out to 24 weeks Data from the second cohort showed improvements in eosinophil counts and histological scores out to 12 weeks suggesting a dose response over the first cohort Data...
Eupraxia Pharmaceuticals to Present Initial Results from Ongoing Phase 1b Study of EP-104GI for the Treatment of Eosinophilic Esophagitis at Upcoming Digestive Disease Week Annual Meeting 2024
VICTORIA, BC , May 14, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology to optimize drug delivery for applications with significant unmet need, today announced that...
Eupraxia Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
Eupraxia common shares now listed on the Nasdaq Capital Market ("Nasdaq") under the symbol "EPRX" Additional data from RESOLVE study evaluating EP-104GI for the treatment of eosinophilic esophagitis ("EoE") expected in the second quarter of 2024 Annual general and special meeting...
Source: https://incomestatements.info
Category: Stock Reports